Complete financial analysis of Voyageur Pharmaceuticals Ltd. (VYYRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Voyageur Pharmaceuticals Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- SHUAA Partners Acquisition Corp I (SHUA) Income Statement Analysis – Financial Results
- Asiasoft Corporation Public Company Limited (AS.BK) Income Statement Analysis – Financial Results
- Future Vision II Acquisition Corp. (FVN) Income Statement Analysis – Financial Results
- $ Sheffield Green (SGR.SI) Income Statement Analysis – Financial Results
- SOFTRAK VENTURE INVESTMENT LTD (SOFTRAKV.BO) Income Statement Analysis – Financial Results
Voyageur Pharmaceuticals Ltd. (VYYRF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://voyageurpharmaceuticals.ca
About Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the pharmaceutical barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.19K | 2.91K | 2.25K | 1.48K | 2.12K | 0.00 | 0.00 | 113.54K | 137.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.19K | -2.91K | -2.25K | -1.48K | -2.12K | 0.00 | 0.00 | -113.54K | -137.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 527.56K | 496.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 376.16K | 1.22M | 1.55M | 999.56K | 552.77K | 866.03K | 655.74K | 571.39K | 108.83K | 0.00 | 45.33K | 85.52K | 0.00 |
| Selling & Marketing | 280.94K | 527.56 | 496.51 | 0.00 | 0.00 | 0.00 | 0.00 | -519.07K | -107.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.22M | 1.22M | 1.55M | 999.56K | 552.77K | 866.03K | 655.74K | 52.32K | 1.48K | 94.46K | 45.33K | 85.52K | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 13.73K | 2.60K | 26.88K | 40.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.22M | 1.75M | 2.05M | 1.00M | 554.89K | 866.03K | 655.74K | 52.32K | 1.48K | 94.46K | 45.33K | 85.52K | 0.00 |
| Cost & Expenses | 1.22M | 1.75M | 2.05M | 1.00M | 554.89K | 866.03K | 655.74K | 52.32K | 1.48K | 94.46K | 45.33K | 85.52K | 0.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 3.28K | 18.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.19K | 2.91K | 2.25K | 1.48K | 2.12K | 845.76K | 615.01K | 698.17K | 246.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -1.22M | -1.75M | -2.05M | -1.12M | -550.17K | 0.00 | 0.00 | -520.00 | 0.00 | -94.46K | -45.33K | -85.52K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.22M | -1.75M | -2.05M | -848.94K | -554.89K | -1.15M | -615.36K | -52.32K | -1.48K | -94.46K | -45.33K | -85.52K | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -178.52K | -1.97K | -3.28K | -154.84K | -21.83K | 289.90K | -55.74K | -516.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -1.40M | -1.75M | -2.05M | -1.14M | -552.29K | -555.86K | -670.75K | -52.32K | -1.48K | -94.46K | -45.33K | -85.52K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.97K | -1.00 | 152.10K | -169.74K | -444.43K | -40.38K | -5.49K | -246.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -1.40M | -1.75M | -2.05M | -1.14M | -552.29K | -555.86K | -670.75K | -52.32K | -1.48K | -94.46K | -45.33K | -85.52K | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | -0.05 | 0.00 | -0.09 | -0.05 | -0.14 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | -0.05 | 0.00 | -0.09 | -0.05 | -0.14 | 0.00 |
| Weighted Avg Shares Out | 130.51M | 107.83M | 94.68M | 70.53M | 57.54M | 47.52M | 36.40M | 1.01M | 1.01M | 1.01M | 1.01M | 626.52K | 925.00K |
| Weighted Avg Shares Out (Dil) | 130.50M | 107.83M | 94.68M | 70.53M | 57.54M | 47.52M | 36.40M | 1.01M | 1.01M | 1.01M | 1.01M | 626.52K | 925.00K |
Voyageur Pharmaceuticals wins US$1.9M sales contract for SmoothX 2% barium contrast product
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced it has secured its first international distribution agreement for its Smoothx 2% imaging contrast product with a sales commitment of US$1.9 million (C$2.6 million) over the first three years of commercialization. Investors welcomed the...
Voyageur Pharmaceuticals poised to shake up medical imaging market with API partnership
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) is set to shake up the medical imaging market with its innovative barium, iodine, and carbon-active pharmaceutical ingredients and contrast agents which are being fast-tracked towards commercialization through a new partnership with Alberta non-profit Applied...
Voyageur Pharmaceuticals to fast-track commercialization of imaging contrast agents through API partnership
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced that it has signed a Master Services Agreement with Applied Pharmaceutical Innovation (API), an industry-funded not-for-profit organization which drives life sciences commercialization, to accelerate the development, manufacturing, and commercialization of Voyageur's imaging contrast agents....
Voyageur Pharmaceuticals initiates international expansion with 'pivotal' alliance
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) told investors it has formalized a sales and distribution alliance with an internationally recognized pharmaceutical distribution company in Central America. Describing it as “pivotal,” the company said the landmark agreement marks a significant milestone in...
Voyageur Pharmaceuticals achieves milestone in the development of HDXBa barium contrast media
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) told investors it has completed the formulation and engineering for production processing of its dry powdered barium contrast media product HDXBaTM. The company explained in a statement that HDXBaTM is an oral contrast agent for...
Voyageur Pharmaceuticals appoints seasoned executive to board; files interim financial statements
Voyageur Pharmaceuticals said it is adding experienced finance and accounting professional Kevin R. McBeth to its board following the retirement of board member Ron Sifton after a term of three and a half years.
Large-scale fullerene production opens up world of possibilities in medicine, electronics
A Calgary-based company has unveiled a new process to produce fullerenes and their derivatives, which are among the world's most valuable materials, on a large scale. Fullerenes are hollow spherical structures composed of interconnected carbon atoms with unique properties that...
Voyageur Pharmaceuticals says white paper highlights SmoothX's potential as oral contrast agent
Voyageur Pharmaceuticals has highlighted a new white paper that outlines the imaging properties of its product SmoothX and its potential to optimize abdominal CT examinations and maximize patient satisfaction. The white paper, titled ‘SmoothX: A Promising New Positive Oral Contrast...
Voyageur Pharmaceuticals completes field work at Frances Creek project in British Columbia
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced that it has successfully completed the environmental and geotechnical field work at its Frances Creek project site in British Columbia. The company said the milestone represents a significant achievement for Voyageur Pharmaceuticals and its...
Voyageur Pharmaceuticals unveils pioneering agreement with Rain Cage Carbon
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced a new development and license agreement with Rain Cage Carbon Inc to develop cutting-edge nanocarbon/fullerene-based contrast agents using Rain Cage's innovative EDEN carbon capture technology. By utilizing nanocarbons produced by the EDEN system, Voyageur aims...
Source: https://incomestatements.info
Category: Stock Reports